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Abstract
Peptides function as signaling molecules in species as diverse as humans and yeast. Mass
spectrometry-based peptidomics techniques provide a relatively unbiased method to
assess the peptidome of biological samples. In the present study, we used a quantitative
peptidomic technique to characterize the peptidome of the yeast Saccharomyces cerevi-
siae and compare it to the peptidomes of mammalian cell lines and tissues. Altogether, 297
yeast peptides derived from 75 proteins were identified. The yeast peptides are similar to
those of the human peptidome in average size and amino acid composition. Inhibition of
proteasome activity with either bortezomib or epoxomicin led to decreased levels of some
yeast peptides, suggesting that these peptides are generated by the proteasome. Approxi-
mately 30% of the yeast peptides correspond to the N- or C-terminus of the protein; the
human peptidome is also highly represented in N- or C-terminal protein fragments. Most
yeast and humans peptides are derived from a subset of abundant proteins, many with
functions involving cellular metabolism or protein synthesis and folding. Of the 75 yeast pro-
teins that give rise to peptides, 24 have orthologs that give rise to human and/or mouse
peptides and for some, the same region of the proteins are found in the human, mouse, and
yeast peptidomes. Taken together, these results support the hypothesis that intracellular
peptides may have specific and conserved biological functions.
Introduction
Peptides perform a number of diverse functions in organisms from yeast to humans. Many
chemical intercellular messengers are peptides, such as mammalian peptide hormones and
neuropeptides [1,2]. Some species of yeast also use peptides to signal as pheromones or mating
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signals, such as alpha-mating factor and a-mating factor of Saccharomyces cerevisiae [3,4]. In
higher eukaryotes with a functional immune system (i.e. jawed vertebrates), peptides produced
within the cell by proteasome-mediated cleavages are displayed on the cell surface attached to
Major Histocompatibility Complex (MHC) proteins and function in immune system recognition
[5–7]. Only peptides that are a specific length (typically 9–10 amino acids), contain certain
sequencemotifs, and which are transported into the lumen of the endoplasmic reticulum can
potentially bind to MHC proteins; these represent an extremely small fraction of all proteasome-
mediated cleavages, and the vast majority of proteasome products are thought to be rapidly
degradedwithin seconds by cellular peptidases [8–10]. One of the arguments made to support
the rapid degradation of intracellular peptides was that if these peptides were not removed, they
would wreak havoc on cellular activity [8]. For example, synthetic peptides are widely used to dis-
rupt protein functionwithin cells [11,12], and endogenous peptides could potentially cause
numerous effects if they were allowed to accumulate within cells. However, if the production and
degradation of intracellular peptides was tightly controlled, these peptides could provide a mech-
anism for regulation of protein-protein interactions or other biochemical functions.
Peptides derived from intracellular proteins have been identified in a number of studies using
mass spectrometry-basedtechniques [13–23]. Peptidomics studies on mouse brain identified
approximately one thousand distinct peptides, with the majority derived from proteins normally
present within the cytosol,mitochondria, or nucleus [16]. A recent study on rat hypothalamus
detected over 16,000 unique peptides, and a large fractionwere derived from intracellular pro-
teins [23]. Peptidomics studies on human cell lines identified hundreds of peptides, nearly all of
which were derived from intracellular proteins [17]. Some of the peptides detected in the human
cell lines were derived from abundant proteins, but only a small subset of the most abundant pro-
teins was reflected in the pool of detected peptides [17]. Levels of nearly all of the intracellular
peptides in several different human and mouse cell lines were altered by treatment of cells with
proteasome inhibitors, suggesting that these peptides are proteasome products [19–22]. The pro-
teasome cleaves a typical protein into dozens of distinct peptides, but for most proteins only 1–2
peptide fragments were detected for each protein [17,19–22]. This is consistent with the idea that
most, but not all, proteasome products are rapidly degraded by intracellular enzymes. Those pep-
tides that are not rapidly degradedmay be protected by interactions with cellular proteins, and
these interactions may alter the function of the cellular proteins.
The catalytically active subunits of the proteasome, as well as most other components of the
proteasome complex, are highly conserved between human and Saccharomyces cerevisiae
[24,25]. This species of yeast has been very well studied in terms of mRNA levels, protein levels,
protein synthesis rates, and protein degradation rates [26–33]. However, no previous study has
examined the yeast peptidome. In the present study, we analyzed the peptidome of wild-type
yeast. Because peptides in mammalian cell lines are affected by treatment with proteasome
inhibitors, we tested whether proteasome inhibitors altered the levels of peptides in wild-type
yeast as well as strains deleted for plasma membrane-boundmulti-drug transporters (PDR5
and SNQ2). To further explore the role of specific proteasome forms, we examined the levels of
peptides in a yeast strain lacking the proteasome activator BLM10. The results of these analyses
reveal striking similarities between the yeast and human peptidome, indicating that some prop-
erties of the peptidome have been highly conserved through evolution.
Materials and Methods
Materials
All reagents were purchased from Sigma unless otherwise indicated. Yeast nitrogen base with
ammonium sulfate was obtained fromMP Biomedicals. Dulbecco’s Phosphate Buffered Saline
The Yeast Peptidome
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(DPBS) was obtained from Invitrogen. Bortezomib and epoxomicin were purchased from LC
Laboratories and Millipore, respectively. Acetonitrile was obtained from Fisher. Hydrochloric
acid, trifluoroacetic acid (TFA) mass spectroscopy grade and C-18 spin columns were pur-
chased from Pierce Thermo Scientific. Succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin
(Suc-Leu-Leu-Val-Tyr-AMC) was obtained from Bachem. The isotopic labeling reagents 4-tri-
methylammoniumbutyryl-N-hydroxysuccinimide (TMAB-NHS) containing either 0, 3, 6, or 9
atoms of deuterium (D0-, D3-, D6-, and D9-TMAB-NHS, respectively) were synthesized as
described [34]. The blm10Δ::NatMX3 strain yMS63 [35] and its isogenic wild-type BY4741
parent MATa his3Δ1 leu2Δ0met15Δ0 ura3Δ0 [36,37] were obtained fromMarion Schmidt
(Department of Biochemistry, Albert Einstein College of Medicine). The deletion strains
pdr5Δ::KanMX4 and snq2Δ::KanMX4 in BY4741 were generated in the yeast deletion project
[38].
Yeast culture for peptidomic analyses
Yeast cells were grown at 30°C to early log phase (less than 1.0 OD600) in synthetic complete
medium (0.67% yeast nitrogen base with ammonium sulfate and 2% glucose, supplemented
with histidine, leucine, uracil and methionine). Cells were collected by centrifugation at
3,000 × g for 5 min, washed with DPBS, and recentrifuged. For some experiments, the pellet
was resuspended in 80°C lysis buffer (50 mMNaH2PO4, 50 mMNaCl, and 50 mMMgCl2) at a
volume of 0.4 × mass of the pellet and immediately incubated in an 80°C water bath for 20 min
to inactivate proteases. Cell lysates were prepared by freezing in liquid nitrogen prior to break-
age in a RetschMM301 grindingmill according to the manufacturer’s instructions. In other
experiments, the cell pellet was resuspended in 80°C water and incubated at this temperature
for 20 min to inactivate proteases, cooled to room temperature, combined with glass beads and
ground using a Mini-Beadbeater (BioSpec Products) for 8 cycles of 30 s each, with a 2 min
incubation on ice between each cycle. There was no major difference in the peptide composi-
tion between these two cell breakage methods. The cell lysate was dissolved in water, cooled on
ice for 10 min, and acidifiedwith HCl to a final concentration of 10 mM. After 15 min incuba-
tion on ice, the suspension was centrifuged at 13,000 × g for 30 min at 4°C. The supernatant
was removed, combined with 250 μL of dibasic sodium phosphate (0.4 M, pH 9.5) and stored
at -80°C until labeling.
For proteasome inhibitor studies, yeast cells were grown to early log phase (less than 1.0
OD600), split into two equal volumes and treated with 1 μM or 10 μM bortezomib, 4 μM epox-
omicin, or a comparable amount of DMSO (maximum 0.1%) for 1 hour. Independent dupli-
cate cultures were grown to generate control and inhibitor-treated biological replicates, as
shown in S1 Fig. The cells were collected by centrifugation at 3,000 × g for 5 min, washed with
DPBS supplemented with the proteasome inhibitor at the same concentration as used for the
treatment, and centrifuged again. Peptides were extracted from cell pellets as described above.
For the studies comparing the effect of the Blm10 proteasome cap on the cellular peptidome,
the blm10Δ strain yMS63 and the isogenic wild-type strain BY4741 were used [36,37]. The
growth conditions, harvesting, and peptide extractionwere similar to that described above.
Proteasome activity assay
Wildtype, PDR5 and SNQ2 gene deletion strains were grown to early log phase and treated
with proteasome inhibitors as described above. The cells were collected by centrifugation at
3,000 × g for 5 min, followed by two washes with water. The pellet was resuspended in 1 ml
water, ground with glass beads using a Mini-Beadbeater (BioSpec Products), and centrifuged at
13,000 × g for 5 min at 4°C. A fraction of the supernatant was incubated in 50 mM Tris HCl
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buffer, pH 7.5, containing 40 mMKCl, 5 mMMgCl2, 0.5 mMATP, 1 mMDTTwith 100 μM
of the proteasome substrate Suc-Leu-Leu-Val-Tyr-AMC at 37°C for 1 hour. After incubation,
proteasomal activity was quantified by fluorescencemeasurement of the substrate (380 nm
excitation, 460 nm emission).
Isotopic labeling
Quantitative peptidomics was performedusing isotopic forms of trimethylammoniumbutyrate
(TMAB) activated with N-hydroxysuccinimide (NHS), synthesized and used as described [34].
Each group within an experiment (control/treated) was labeled with a different isotopic tag, as
shown in S1 Fig. The TMAB-NHS labels were dissolved in DMSO to a concentration of
400 μg/μL and 7.5 mg of label was used per sample. The pH of the peptide extract was adjusted
to 9.5 with 1 M NaOH at the start of the experiment. Labeling was performed over 8 rounds;
2.3 μL of the label was added to the extract every 20 min. The pH was measured between each
round and if necessary, brought back to 9.5 for the first five rounds. For rounds 6–8, the pH
was not adjusted after the addition of the TMAB-NHS reagent. After the final round of label-
ing, the pH was adjusted to 9.5 again, extracts were incubated at room temperature for 90 min,
following which 30 μL of 2.5 M glycine was added to quench unreacted label. After 40 min of
incubation at room temperature, the labeled extracts for a single experiment were pooled and
filtered through Amicon Ultracel-10 K units. 30 μL of a 2 M solution of hydroxylamine hydro-
chloride was added over three rounds to the pooled and filtered sample to hydrolyze any
labeled tyrosines. The pH was measured after the addition of hydroxylamine and adjusted to
9.0 with 1 M NaOH. Samples were desalted through C-18 spin columns and peptides were
eluted using 160 μL of 0.5% TFA and 70% acetonitrile. Samples were freeze-dried in a vacuum
centrifuge and stored at −80°C until analysis by mass spectrometry.
Mass spectrometry
The LC-MS/MS experiments were performed on a Synapt G2 mass spectrometer coupled to a
nanoAcquity capillary liquid chromatography (LC) system (Waters, Milford, MA, USA). The
peptidemixture was desalted online for 3 min at a flow rate of 5 μL/min of phase A (0.1% for-
mic acid) using a Symmetry C18 trapping column (5-μm particles, 180-μm inner diameters,
20-mm length;Waters). The mixture of trapped peptides was subsequently separated by elu-
tion with a gradient of 7–65% of phase B (0.1% formic acid in acetonitrile) through a BEH 130
C18 column (1.7-μm particles, 75-μm inner diameters, 100-mm length;Waters) in 42 min.
The data were acquired in the data-dependent mode and the MS spectra of multiple-charged
protonated peptides generated by electrospray ionization were acquired for 0.2 s fromm/z
300–1600. The three most intense ions exceeding base peak intensity threshold of 2500 counts
were automatically mass selected and dissociated in MS/MS by 15- to 60-eV collisions with
argon for 0.2 s. The typical LC and electrospray ionization conditions consisted of a flow rate
of 250 nL/min, a capillary voltage of 3.0 kV, a block temperature of 70°C, and a cone voltage of
50 V. The dynamic peak exclusion windowwas set to 90 s.
Quantification of relative peptide levels
The MS spectra were manually evaluated. The intensity of the monoisotopic peaks of peptide
containing each of the isotopic labels was logged into a spreadsheet. If a peptide was found
with multiple charge states, the peak intensity of each state was averaged to arrive at a single
number for the relative level of each isotopically-tagged form. See S1 Fig for details on the
labeling strategy and the number of replicates. Every experiment included two biological repli-
cates of each treated and control group, as shown in S1 Fig.
The Yeast Peptidome
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MS/MS identification of peptides
Peptides were identified by MS/MS sequencing using the Mascot program (Matrix Science) fol-
lowed by manual verification of the spectra using MassLynx, version 4.0 (Waters). The data-
base searched was SwissProt_AC_20150324, limited to yeast Saccharomyces cerevisiae (7,904
sequences). No cleavage site was specified, and variable post-translational modifications
selected for the searches included the TMAB labels (termed ‘GIST’ in Mascot), N-terminal pro-
tein acetylation, methionine oxidation, and cyanylation of Cys. The Mascot results were manu-
ally evaluated to exclude false positives, based on previously established criteria [34,39,40].
These criteria are listed in S1 Appendix along with representative data showing the evaluation
process for a peptide with a lowMascot score. S2 Appendix shows the evaluation of another
peptide which failed to meet the criteria. Supplemental files show the sequences (including
cleavage sites) for the yeast peptides (S1 Table) and their precursor proteins/genes, including
Mascot scores (S2 Table). The mass spectrometrydata for the yeast peptidomics analyses have
been deposited to the ProteomeXchange Consortium [41] via the MassIVE partner repository
(MassIVE ID: MSV000080119).
The human peptidome was compiled from previous studies on human cell lines HEK293T,
SH-SY5Y, and MCF-7 cell lines [17,19–21,42]. In addition, recent peptidomic data using the
RPMI-8226 cell line were included; these analyses were performed using identical procedures
as those used for the other cell lines [17]. Peptides detected in untreated cells were included in
the compiled human peptidome database; those peptides only detected in cells treated with
proteasome inhibitors or other reagents were excluded from the database. Supplemental files
show the sequences (including cleavage sites) for the human peptides (S3 Table) and their pre-
cursor proteins/genes (S4 Table). The mouse peptidome was previously reported [16].
Results
Altogether, 297 unique peptides were identified fromMS/MS analysis of the 5 LC/MS runs per-
formed in this study (S1 Table). Additional peptides were detected in the MS spectra but could
not be identified, either because no MS/MS data were obtained or the quality of the MS/MS
spectra were not sufficient to determine the peptide sequence. The 297 identified peptides were
derived from 75 distinct proteins/genes (S2 Table). Approximately one half of the identified
peptides arose from 8 proteins. The average mass of the yeast peptides is 1640 Da, the median
is 1523 Da, and 90% of the peptides are between 900 and 3000 Da (Fig 1). The amino acid com-
position of the peptides shows the most abundant amino acid is Ala (10.6%), with Lys, Val,
Leu, Gly, Asp, and Glu also abundant (Table 1). Cys is not detected in the peptidome, but this
omission is likely to be an artifact of the extraction and/or labeling procedure [43]. Otherwise,
the amino acid composition of the peptidome is generally similar to the amino acid composi-
tion of the intracellular and nuclear yeast proteome [44].
To compare the yeast peptidome with the human cell line peptidome, we compiled a master
list of all peptides that were identified in peptidomics studies on HEK293T, SH-SY5Y, MCF7,
and RPMI-8226 cells [17,19–21,42]. These previous studies included 83 LC/MS runs. Alto-
gether, this combined dataset contains 627 distinct peptides (S3 Table) that are derived from
153 distinct proteins/genes (S4 Table). Additional human peptides were detected by MS analy-
sis but their identities could not be determined from the MS/MS analysis. Thus, both yeast and
human datasets reflect a subset of the total number of peptides detected by MS. Although a
greater number of human peptides were identified than yeast peptides, this does not necessarily
mean that human cells have more peptides than yeast; many more LC/MS runs of human pep-
tides were analyzed and the total numbers of identified peptides cannot be compared between
human and yeast.
The Yeast Peptidome
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The size distribution of the identified human peptides is very similar to that of yeast pep-
tides, with an average mass of 1675 Da and medianmass of 1559 Da for the human peptides
(Fig 1). As with the yeast peptides, 90% of the identified human peptides were between 900 and
3000 Da (Fig 1). The amino acid composition of the human peptides is very similar to that of
Fig 1. Comparison of the size distribution of peptides in human cell lines and yeast. The 627 peptides identified in human cell
lines and the 297 peptides identified in yeast were each sorted by rank of the peptide’s molecular mass and plotted. For the human
peptidome, the average mass was 1675 Da and the median was 1559 Da. For the yeast peptidome, the average mass was 1640 Da
and the median was 1523 Da.
doi:10.1371/journal.pone.0163312.g001
The Yeast Peptidome
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the yeast peptides (Table 1). Neither the yeast nor human peptides are enriched in residues
such as Pro that are resistant to the common cellular aminopeptidases (Table 1). The most
common N-terminal amino acid is Ala in both the yeast (14%) and human peptidome (16%).
Other common N-terminal amino acids are Leu, Ile, Ser, Val, and Gly; these residues are pres-
ent on the N-terminus of approximately half of the yeast and human peptides (S1 and S3
Tables). Only 9% of the yeast peptides and 21% of the human peptides have N-terminal acetyl
groups. These numbers are consistent with the finding that 15% of the yeast peptides and 26%
of the human peptides represent the N-terminal fragment of the protein (discussed below) and
57% of yeast proteins and 84% of human proteins are N-terminally acetylated [45]. Thus, the
presence of N-terminal acetyl groups on the yeast and human peptides is a reflection of the
proteins from which the peptides are derived, and does not deviate from the expected
frequency.
A previous analysis of intracellular mouse brain peptides found that close to one half of the
peptides represented the N- or C-terminus of the protein [16]. In contrast, proteomic studies
that digest proteins with trypsin prior to MS analysis detect mainly peptides that are internal
fragments of the protein [43]. Similar to the previous report on intracellular mouse peptides,
43% of the human cell line peptides represent either the N-terminus (26%) or C-terminus
(17%) of the proteins from which the peptides are derived (Fig 2). The yeast peptidome also
shows an abundance of peptides derived from the N-terminus (15%) and C-terminus (14%) of
the proteins (Fig 2), relative to the predicted abundance of<1% based on consideration of the
average size of the peptides and proteins from which they are produced.
The method used to extract peptides from yeast avoided hot acid which causes hydrolysis of
Asp-Pro bonds [46]. None of the yeast peptides detected in our analysis resulted from cleavage
Table 1. Amino acid composition of peptides found in human cell lines and yeast cells.
Human Peptides Yeast Peptides Yeast Proteins—Intracellular Yeast Proteins—Nuclear
# % # % % ± SD % ± SD
A 866 9.1 471 10.6 7.9 ± 2.9 8.3 ± 5.0
C 3 0.0 0 0.0 1.9 ± 2.4 1.6 ± 1.7
D 645 6.8 335 7.5 5.5 ± 2.0 4.7 ± 2.6
E 690 7.2 322 7.2 7.1 ± 3.2 6.5 ± 3.6
F 376 3.9 135 3.0 3.9 ± 1.8 2.7 ± 1.7
G 787 8.3 342 7.7 7.1 ± 2.6 6.3 ± 2.8
H 137 1.4 73 1.6 2.1 ± 1.4 2.1 ± 1.4
I 502 5.3 235 5.3 5.2 ± 2.0 3.7 ± 2.0
K 696 7.3 392 8.8 6.7 ± 2.8 7.9 ± 6.5
L 900 9.4 359 8.1 8.6 ± 2.4 7.4 ± 3.2
M 164 1.7 40 0.9 2.4 ± 1.3 2.3 ± 1.2
N 309 3.2 202 4.5 4.0 ± 1.8 3.7 ± 2.2
P 560 5.9 225 5.1 5.3 ± 4.0 6.9 ± 3.4
Q 395 4.1 172 3.9 4.4 ± 3.0 4.7 ± 2.8
R 392 4.1 131 2.9 4.9 ± 2.2 8.7 ± 13.5
S 634 6.7 304 6.8 6.6 ± 2.0 8.8 ± 3.2
T 438 4.6 241 5.4 5.3 ± 1.7 5.1 ± 2.1
V 813 8.5 377 8.5 6.8 ± 1.9 5.3 ± 1.8
W 70 0.7 9 0.2 1.2 ± 0.8 0.7 ± 0.7
Y 156 1.6 87 2.0 3.1 ± 1.5 2.4 ± 1.3
SD, standard deviation. The amino acid composition of yeast proteins is from Cedano et al [44].
doi:10.1371/journal.pone.0163312.t001
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at Asp-Pro sites. Pro was not very common in the P1 position of the cleavage site; only one
yeast peptide and two human peptides resulted from cleavage of a Pro-Xaa bond. Acidic resi-
dues (Asp, Glu) were found in the P1 position of the cleavage site of 11% of the yeast peptides
and 4% of the human peptides. Basic residues (Lys, Arg) were found in the P1 position of the
cleavage site of 22% of the yeast peptides and 13% of the human peptides. Hydrophobic resi-
dues (Leu,Met, Val, Ala, Phe, Tyr, and Trp) were found in the P1 position of approximately
one half of the cleavage sites for both yeast and human peptides (S1 and S3 Tables).
The proteasome is known to cleave intracellular proteins into peptides, with the major
active subunit (beta 5) preferring hydrophobic residues in the P1 position, and the other two
active subunits (beta 1 and beta 2) cleaving at sites with acidic and basic P1 residues, respec-
tively [25,47]. Previously, the peptides in human cell lines were found to be greatly affected by
treatment of cells with proteasome inhibitors, suggesting that these peptides are proteasome
products [19–21]. To test if the peptides present in yeast are produced by the proteasome, cells
were incubated with bortezomib or epoxomicin for 1 hour and then processed for peptidomics.
Replicates of the same strain of yeast, grown under the same conditions except for the absence
of inhibitor, were similarly processed. Peptides were labeled with isotopic tags so that replicates
of treated cell extracts could be directly compared to replicates of untreated cell extracts in the
same LC/MS run (S1 Fig). The level of each peptide in one replicate was compared to the aver-
age intensity of the peptide in the two untreated control replicates. This analysis was performed
for both of the treated samples in each LC/MS run, as well as for the two untreated control rep-
licates; the latter provided a measure of the normal variation of the peptide between replicates.
Relative levels of the peptide detected in each experiment are shown in S5 Table. To visualize
all of the data, the relative level of each replicate was plotted on a rank plot; for these plots, the
y-axis represents the relative level and the x-axis is the rank (Fig 3). Treatment of wild-type
Fig 2. Location of peptides within proteins. C-term refers to peptides that contain the C-terminal residue of the protein. N-term
includes peptides with the N-terminal initiation Met as well as peptides with this Met removed (including acetylated peptides). A small
number of proteins are known to contain precursor sequences that are cleaved to produce the mature form of the protein, and several of
the human N-terminal peptides correspond to the N-terminus of the mature form. See S1 and S3 Tables for peptide sequences.
doi:10.1371/journal.pone.0163312.g002
The Yeast Peptidome
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yeast with 1 μM bortezomib did not produce major changes in the levels of intracellular pep-
tides (Fig 3). Subsequent analysis in which the control values were pooled for each peptide
detected in three or more LC/MS runs found only one peptide to be significantly altered in the
wild-type yeast treated with 1 μM bortezomib. This peptide, a fragment of the ENO2 gene
product, was elevated by 1 μM bortezomib treatment (Table 2).
Fig 3. Effect of bortezomib or epoxomicin on relative levels of peptides in yeast. Wild type yeast (top panel)
or yeast deleted for drug transporter genes PDR5 (second panel) or SNQ2 (bottom two panels) were treated with
proteasome inhibitors for 1 hour and then processed for peptidomics as described in Materials and Methods. See
S1 Fig for labeling scheme used for quantitative peptidomics. Wild-type yeast were treated with 1 μM bortezomib,
the pdr5Δ and snq2Δ strains were treated with 10 μM bortezomib, the snq2Δ strain was treated with 4 μM
epoxomicin and control replicates were treated with a comparable amount of drug vehicle alone (maximum 0.1%
DMSO). Each replicate was compared to the average level of that peptide in the control replicates and the
individual ratios sorted by rank and plotted. The y-axis represents the relative level of each replicate, comparing
either drug-treated to the average control values (red) or the control replicates to the average control values
(black). See S5 Table for relative peptide levels of each peptide in the various treatments.
doi:10.1371/journal.pone.0163312.g003
Table 2. Peptides found in three or more LC/MS runs of yeast cell extracts.
Control bortez/cont in pdr5Δ
yeast
bortez/cont in
snq2Δ yeast
epox/cont in snq2Δ
yeast
bortez/cont in WT
yeast
Gene Peptide Avg SEM n Avg SEM p Avg SEM p Avg SEM p Avg SEM p
ADH1 STLPEIYEK 1.00 0.08 6 1.95 0.25 ** 0.93 0.21 NS 1.02 0.22 NS ND
APE3 SPPVDGFVGK 1.00 0.16 6 1.95 0.11 * 0.93 0.38 NS 0.85 0.39 NS ND
APE3 SEKLQDKIKVD 1.00 0.07 6 1.42 0.21 * 1.28 0.18 NS 0.69 0.19 NS ND
APE3 NIIADTKHGDPDNI 1.00 0.14 6 0.34 0.06 * 1.13 0.44 NS 0.94 0.09 NS ND
ENO2 AVSKVYA 1.00 0.17 8 2.58 0.17 ** 2.46 1.11 * 1.27 0.26 NS 1.53 0.63 NS
ENO2 QIGTLSESIK 1.00 0.07 8 1.68 0.19 ** 0.74 0.13 NS 0.99 0.27 NS 1.18 0.18 NS
ENO2 QIGTLSESIKA 1.00 0.03 8 1.41 0.02 *** 1.90 0.13 *** 0.97 0.19 NS 1.21 0.21 NS
ENO2 GVELADMYHS 1.00 0.13 8 1.84 0.35 * 1.76 0.77 NS 1.59 0.01 NS 2.02 0.16 **
ENO2 TAIEKKAADAL 1.00 0.05 8 1.45 0.09 ** 1.32 0.06 * 1.06 0.19 NS 1.28 0.16 NS
ENO2 GHDGKVKIGLD 1.00 0.13 8 0.93 0.04 NS 1.12 0.58 NS 0.79 0.01 NS 1.30 0.15 NS
ENO2 ADLSKSKTSPY 1.00 0.09 6 0.70 0.06 NS 1.21 0.56 NS ND 1.20 0.07 NS
ENO2 SLDGTANKSKLGA 1.00 0.06 8 0.19 0.07 *** 0.20 0.01 *** 1.09 0.26 NS 1.22 0.15 NS
ENO2 SLDGTANKSKLGAN 1.00 0.08 8 1.54 0.22 * 1.25 0.21 NS 0.86 0.19 NS 1.28 0.28 NS
ENO2 SLDGTANKSKLGANA 1.00 0.08 8 0.28 0.01 * 0.24 0.02 *** 1.10 0.27 NS 0.90 0.19 NS
ENO2 NLDVKDQKAVDDF 1.00 0.09 6 0.47 0.01 *** 0.54 0.06 *** 1.00 0.10 NS ND
GAS1 DDVPAIEVVGNKF 1.00 0.02 6 1.09 0.17 NS 0.80 0.17 * 1.01 0.01 NS ND
PEP4 GKFDGIL 1.00 0.14 8 5.73 0.82 *** 6.70 1.07 *** 1.38 0.10 NS 1.60 0.23 NS
TDH1 YDSTHGRYKGT 1.00 0.11 6 1.10 0.04 NS 0.98 0.13 NS ND 1.40 0.45 NS
TDH3 STGVFKEL 1.00 0.16 6 2.18 0.35 * 0.82 0.10 NS 1.08 0.07 NS ND
TPI1 VDIINSRN 1.00 0.13 8 0.59 0.02 NS 1.80 0.68 NS 1.83 0.80 NS 1.28 0.27 NS
TPI1 VKKPQVTVGAQ 1.00 0.06 8 2.70 0.04 *** 2.06 0.41 *** 1.19 0.46 NS 1.25 0.23 NS
TPI1 GAFTGENSVDQIK 1.00 0.16 8 1.31 0.24 NS 1.56 0.32 NS 2.02 0.04 * 1.33 0.17 NS
TPI1 GLAATPEDAQDIHA 1.00 0.08 8 0.34 0.13 ** 0.53 0.08 * 1.44 0.07 * 1.14 0.13 NS
TPI1 ASGAFTGENSVDQIK 1.00 0.11 8 0.98 0.20 NS 0.91 0.13 NS 2.15 0.47 ** 1.40 0.01 NS
TPI1 GAFTGENSVDQIKDVGAK 1.00 0.08 6 ND 2.40 0.59 ** 1.23 0.14 NS 1.09 0.15 NS
Abbreviations: Avg, average; SEM, standard error of the mean; NS, not statistically significant (i.e. p>0.05); ND, not detected; and p, p-value
*, p<0.05
**, p<0.01
***, p<0.001 compared to untreated control group using Student’s t-test.
doi:10.1371/journal.pone.0163312.t002
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Because wild-type yeast contain transport proteins that actively pump bortezomib out of
cells, we analyzed PDR5 and SNQ2 gene deletion strains; these genes encodemajor drug trans-
port proteins [48]. The strains lacking the transport proteins were treated with 10 μM bortezo-
mib for one hour, which resulted in a 30–40% reduction of chymotryptic-like proteasome
activity (Fig 4). In each deletionmutant, levels of some peptides showed a dramatic change
upon bortezomib treatment (Fig 3). With the pdr5Δ strain, approximately one half of the iden-
tified peptides showed a 2-fold change (i.e. ratio of<0.5 or>2). For the snq2Δ strain, approxi-
mately one third of the identified peptides showed a 2-fold change (Fig 3). Treatment of the
snq2Δ strain with 4 μM epoxomicin for one hour did not produce major changes in the level of
most peptides (Fig 3). Altogether, 25 peptides were found in three or more LC/MS runs; these
peptides reflect only a subset of all peptides detected in each experiment (see S5 Table for rela-
tive levels of all peptides). The 25 commonly detected peptides were compared, pooling the
control data for each experiment to increase the number of replicates (Table 2). Of these 25
peptides, 17 were significantly affected in the bortezomib-treated pdr5Δ strain extract, with 12
increases and 5 decreases (Table 2). Treatment of the snq2Δ strain with bortezomib resulted in
11 significant changes, with 6 increases and 5 decreases (Table 2). Only 3 of the peptides were
altered with 4 μM epoxomicin, and all of these were elevated (Table 2). The finding that some
peptides are reduced upon treatment with 10 μM bortezomib suggests that these peptides are
products of proteasomal cleavage of cellular proteins. Previous studies on human cell lines
found that bortezomib, epoxomicin, and other proteasome inhibitors reduced the levels of
some peptides but also caused a large elevation in the levels of other peptides [19–21].
Blm10, the yeast ortholog of the mammalian proteasome activator PA200, associates with a
subpopulation of proteasomes and functions in the ubiquitin-independent degradation of pro-
tein [36,37]. In contrast, the 19S proteasome activator functions in ubiquitin-dependent pro-
tein degradation. To evaluate the relative contribution of ubiquitin-dependent and ubiquitin-
independent pathways for the generation of intracellular peptides, we analyzed the peptidome
of wild-type and blm10Δ strains (S1 Fig). All peptides found in the wild-type strain were also
detected in the blm10Δ strain and the relative levels were generally comparable (Fig 5). None of
the identified peptides shows statistically significant differences between the two groups, indi-
cating that the absence of Blm10 does not cause a major change in the level of intracellular
peptides.
All of the analyses described above considered the peptides themselves or the cleavage sites
that generate these peptides. Another level of analysis considers the proteins from which these
peptides are derived. A previous study that examined peptides associated with one of the MHC
proteins, HLA-B27, found both proteasome-dependent and proteasome-independent peptides;
the latter were mainly derived from small proteins [49]. Of the 153 human proteins that corre-
spond to the 627 peptides detected in human cell lines, the average protein length is 253 amino
acids and the median length is 199 amino acids (Fig 6, top); this is smaller than the average
human protein size of approximately 500 amino acids [49]. Similar analysis of the 75 yeast pro-
teins that gave rise to the peptides found in the present study show an average protein length of
353 amino acids and a median length of 310 amino acids. These values are smaller than the
average protein length of 478 amino acids and median length of 384 amino acids for the 5700
yeast proteins analyzed by Arava et al [27].
The finding that the peptidome of both yeast and human cells is derived from proteins that
tend to be smaller than average is contrary to the expectation that large proteins should be
highly represented because they can theoretically generate more peptides and be favored in
peptidomic analysis. For example, tryptic peptide fragments of equimolar amounts of five pro-
teins were analyzed using a peptidomics approach identical to that used in the present study,
and there was a strong positive correlation between the protein’s size and the number of
The Yeast Peptidome
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peptides detected [43]. In the present study, a small subset of proteins is responsible for the
majority of yeast peptides; 8 proteins are responsible for slightly more than half of all peptides
identified (S1 Table). The average length of these 8 proteins is 385 amino acids, which is well
below the average length of yeast proteins.
A previous analysis of the peptidome of human cell lines [17] did not find a correlation
between the peptidome and protein abundance. The limitation of this analysis is that the vast
majority of proteins identified in the peptidomic analysis were not detected in the proteomic
study measuring protein levels [50]. To re-examine the correlation between the peptidome and
protein abundance, the human peptidomewas compared to RNA-seq data for the 4 cell lines
from which the peptidome data was derived: HEK293T, SH-SY5Y, MCF7, and RPMI-8226
[33]. Each of the ~20,000 genes in these datasets was ordered by abundance of mRNA, and the
153 mRNAs that correspond to the peptides identified in the peptidomic analyses were
selected.Of these 153 mRNAs, 77 are within the top 500 ranking of at least one of the four cell
lines used for the various peptidomic studies, and all but 4 are within the top 5000 (Fig 7).
Thus, many of the intracellular peptides in human cell lines are derived from proteins encoded
by abundant mRNAs.
The yeast peptidome was also analyzed for a correlation with RNA and protein abundance.
RNA-seq data for yeast [30] reported values for 5100 genes, and 63 of the proteins found in the
peptidomic analysis were among the transcripts with values listed; 12 were not reported in the
RNA-seq data (Fig 7). The 5100 genes were divided into groups of 510 based on RNA abun-
dance. Of the 510 genes with RNA expression in the highest tenth percentile, 44 corresponded
to genes detected in the peptidomics analysis. Thirteen of the genes corresponding to peptides
were in the 10-20th percentile of RNA expression levels, and the other 7 genes corresponding
to peptides were scattered among the lower percentiles (Fig 7). Similar analysis was performed
to compare the peptidome with protein abundance. Several studies have reported protein
Fig 4. Analysis of proteasome activity in yeast. Aliquots of the PDR5 and SNQ2 gene deletion strains
used for the peptidomics in Fig 3 were tested for proteasome activity using Suc-Leu-Leu-Val-Tyr-AMC, as
described in Materials and Methods. Error bars show standard error of the mean (n = 10). ***, p<0.001
using Student’s t-test.
doi:10.1371/journal.pone.0163312.g004
Fig 5. Comparison of peptide levels in wild-type and BLM10 gene deletion yeast strains. Each replicate was
plotted as described for Fig 3. See S1 Fig for labeling scheme and S5 Table for quantitative data on each individual
peptide. Although there was a slight decrease in the relative level of most peptides in the blm10Δ strain (red)
compared to the wild-type strain (black), based on the range of values for the replicates, these changes were not
statistically significant.
doi:10.1371/journal.pone.0163312.g005
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abundance; the most comprehensive of these is a recent study by Kulak et al that usedMS with
label-free quantification to estimate protein copy number for 4577 yeast genes [51]. These pro-
teins/genes were divided into ~10 groups of 458 based on protein abundance, and 60 of the 75
proteins corresponding to yeast peptides were in the top 10th percentile (Fig 7). Seven of the
peptides were in the 10-20th percentile of protein abundance, and the other 7 were distributed
among the other groups (Fig 7). Similar results were found when analyses were performed for
RNA or protein abundance determined from other techniques such as single molecule
sequencing [31], an epitope-tagged fusion library [28], and mRNA translation profiles [27].
Fig 6. Size distribution of the 153 human proteins and 75 yeast proteins that encode the peptides detected
in the peptidomic analyses. Each group of proteins was sorted by length and plotted by rank (x-axis). Units of the
y-axis are amino acid residues. The average length of human proteins found in the peptidomic analysis is 253
amino acids and the median length is 199 amino acids. The average length of yeast proteins found in the
peptidomic analysis is 353 amino acids and the median length is 310 amino acids.
doi:10.1371/journal.pone.0163312.g006
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Taken together, these results suggest that nearly all of the peptides detected in the present
study are produced from proteins that are among the top 20th percentile in terms of cellular
protein abundance or predicted synthetic rate. However, there are approximately one thousand
Fig 7. Comparison of the proteins found in the human and yeast peptidomics analyses with datasets
estimating mRNA or protein abundance. RNA-Seq data for human cell lines [33] estimated mRNA levels from
fragments per kilobase of transcript per million mapped reads. For each of the cell lines used for the analyses
(HEK293T, SH-SY5Y, MCF7, and RPMI-8226), the 5000 entries with highest rank for any one of these cell lines
were selected. These 5000 genes were divided into 10 groups of 500 genes per group, and the number of matches
found in the peptidome were determined for each of these groups as well as those not within the top 5000 (of which
there were 4 proteins found in the peptidome). Yeast RNA-Seq data [30] included values for 5100 genes; these
were divided into 10 groups of 510. Yeast protein abundance was estimated from a label-free quantitative
proteomics study by Kulak et al [51]. This study reported relative levels of 4577 proteins, and we divided these into
10 groups of 458 proteins based on abundance and the number of proteins corresponding to the peptidome is
indicated for each group.
doi:10.1371/journal.pone.0163312.g007
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proteins in this group and only a small subset was found to be represented in the peptidome.
Thus, abundance alone is not sufficient to predict if peptide fragments will be detected in pepti-
domic studies.
In theory, the cellular peptides should arise from proteins that have high rates of turnover.
The median half-life of 3772 yeast proteins examined by Christiano is 8.8 h [32]. Out of 75 pro-
teins found in peptidomics analysis, 73 were measured in Christiano et al, and these 73 proteins
have a median of 10.6 h (Fig 8). Only 1 of the 73 proteins found in peptidomics had a half-life
3 h, whereas 7% of all proteins had half-lives of 3 h or less [32]. Furthermore, 8% of the pro-
teins found in peptidomics had half-lives of100 h, whereas only 1% of all proteins detected
by Christiano had half-lives of100 h [32]. Thus, the proteins that give rise to the observed
yeast peptides are more stable than average proteins, not less stable as predicted.
Approximately 50% of the 153 human proteins identified in peptidomic studies are anno-
tated as cytosolic, ~30% are nuclear, ~15% are mitochondrial, and ~5% from other compart-
ments or unknown distribution (Fig 9); this is generally similar to our previous analysis
performed on fewer proteins [17]. Analysis of the yeast proteins found in the present peptido-
mics analysis shows the majority to be derived from cytosolic proteins (Fig 9). Like the human
proteins, ~15% of the yeast proteins are mitochondrial. However, only ~15% of the yeast pro-
teins are nuclear, in contrast to the ~30% of the human proteins. A greater fraction of the yeast
proteins are found in vacuoles, endoplasmic reticulum, or secretory pathway, compared to the
human proteins (Fig 9).
Many of the proteins which contribute to the human and yeast peptidome are involved with
basic cellular functions such as metabolism,maintenance of reduction/oxidation balance,
translation/protein synthesis, chaperone/protein folding, protein/vesicle trafficking, and prote-
olysis (Fig 10). However, there are several categories of functions for the human proteins that
are greatly under-represented in the yeast peptidome. Of the 153 human proteins found in the
peptidome, 46 function in transcription or RNA/DNA binding and 16 function in cytoskeletal
dynamics, whereas no yeast peptides were found from proteins with these functions (Fig 10).
Fig 8. Analysis of the turnover rate of proteins found in the analysis of the yeast peptides. Protein half-life
data were reported by Christiano et al [32] and were determined by growing yeast in heavy [13C6/15N2] L-lysine
for many generations, then growing in light lysine for various lengths of time and measuring the ratio of heavy/light
proteins using mass spectrometry-based proteomics. The half-life was capped by Christiano et al at 100 hours.
Out of 75 proteins found in our peptidomics analysis, 73 corresponded to proteins detected by Christiano et al. The
relative half life (log scale) for these 73 proteins and for all 3772 proteins reported by Christiano are plotted as a
percentile of the half-life for each group of proteins.
doi:10.1371/journal.pone.0163312.g008
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Only 2 yeast proteins that function in intracellular signaling and/or regulation of the cell cycle
were found in the peptidome, whereas 21 human proteins found in peptidomic analyses func-
tion in this category (Fig 10). Taken together, these results suggest that while many of the pro-
teins detected in the peptidome of humans and yeast have similar functions, there are some
categories of human proteins that aren’t represented in the yeast peptidome.
To directly compare individual proteins between yeast and human, the 75 yeast proteins
found in the present study were used to search for human orthologs using Blast homology
searches of NCBI databases. Of these 75 proteins, 56 have a clear human ortholog, and 23 of
these orthologs are found in the human and/or mouse peptidome database (Table 3). These
orthologs include a number of proteins associated with ribosomes, cellular metabolic pathways,
and chaperones such as 10 kDa heat shock protein. For some of these orthologs, the peptides
found in the yeast peptidome arise from the same region of the protein as peptides present in
the human and/or mouse peptidomes. The alignment of acyl-CoA-binding protein is shown in
Fig 11, and all alignments of orthologs are included in S2 Fig. In yeast, two N-terminal frag-
ments of acyl-Co-A-binding protein were identified, in human cells a single N-terminal frag-
ment was identified, and in mouse tissues, a number of N-terminal peptides were identified
along with a couple of internal peptides (Fig 11, underlined sequences). The overall amino acid
sequence identity between yeast, mouse, and human acyl-CoA-binding protein is 37% (consid-
ering only exact matches of all three species).Within the 26 residues found in the yeast pepti-
dome, the sequences are slightly less highly conserved,with only 31% identity. A similar
comparison of all 23 orthologs in which peptides were found in yeast and at least one of the
mammalian species (i.e. human and/or mouse) was performed (Table 3). The overall amino
acid identity of the proteins ranged from 17% (for the SBA1 gene product) to 66% (for the
SSA2 gene product), with an average of 46% (Table 3). Considering just the region correspond-
ing to the peptides found in yeast, the amino acid sequence identity ranged from 0% (for the
AHP1 gene product) to 85% (for the SSC1 gene product), with an average of 45% (Table 3).
Thus, the degree of conservation of the region of each protein that was found in the yeast pepti-
dome is comparable to the overall conservation of the proteins, and not more or less highly
conserved.
Discussion
The major finding of this study is that yeast cells contain peptides derived from intracellular
proteins. While it is possible that some of the peptides detected in the present study and in
Fig 9. Intracellular location of proteins found in the peptidomic analysis of human and yeast cells. For
each protein, the major intracellular location reported in UniProt was used. Some proteins were reported to be
equally present in the cytosol as well as another compartment (such as nucleus); in these cases, the non-cytosolic
compartment was selected.
doi:10.1371/journal.pone.0163312.g009
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previous studies on mammalian cell lines represent degradative products generated during
protein extraction, we believe this is unlikely for several reasons. First, only a subset of proteins
is represented in the peptidome, and for most proteins only a small number of peptides are
detected. In contrast, non-specific degradation (such as trypsin-mediateddigestion of proteins)
typically produces a large number of distinct fragments from the major cellular proteins. Sec-
ond, the cells (yeast in this study and mammalian cells in previous studies) were rapidly heated
to 80°C, and no yeast or human proteases are known to be stable to this temperature. A num-
ber of studies have compared various methods of sample preparation for peptidomics and con-
cluded that rapid heat inactivation is a valid method to greatly reduce postmortemprotein
Fig 10. Primary function of proteins found in the peptidomic analysis of human and yeast cells. For each protein, the major
function reported in UniProt was used.
doi:10.1371/journal.pone.0163312.g010
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degradation in tissues [18,23,46,52–55]. Third, the finding that the vast majority of intracellular
peptides detected in mammalian cell lines are greatly reduced by short-term treatment of cells
with proteasome inhibitors such as epoxomicin and MG132 strongly suggests that these are
Table 3. Comparison of proteins found in the yeast peptidome with orthologs in mammalian peptidome (human and mouse).
Yeast
Gene
Human Gene Yeast Yeast
Peptides
Yeast
Protein
Conservation within
peptide
Conservation entire
protein
Name Name Protein Name # of aa # of aa % aa identity % aa identity
ACB1 DBI Acyl-CoA-binding protein 26 87 31% 37%
AHP1 PRDX5 Peroxiredoxin type-2 17 176 0% 22%
CDC19 PKM Pyruvate kinase 1 53 500 49% 49%
CMD1 CALM1 Calmodulin 30 147 43% 56%
ENO2 ENO2 Enolase 2 239 437 58% 61%
GPM1 PGAM2 Phosphoglycerate mutase 1 60 247 48% 51%
HSP10 HSPE1 10 kDa heat shock protein 30 106 43% 44%
PEP4 CTSD* Vacuolar aspartyl protease 34 405 53% 36%
RPL31A RPL31 60S ribosomal protein L31A 16 113 50% 59%
RPP1A RPLP1 60S acidic ribosomal protein
P1α
13 106 46% 51%
RPP2A RPLP2 Ribosomal protein P2 alpha 9 106 56% 51%
RPP2B RPLP2 Ribosomal protein P2 beta 30 110 43% 46%
RPS21A RPS21 40S ribosomal protein S21A 41 87 56% 51%
SBA1 PTGES3 Co-chaperone protein SBA1 24 216 13% 17%
SMT3 SUMO2 Ubiquitin-like protein SMT3 25 101 44% 38%
SOD1 SOD1 Superoxide dismutase [Cu-Zn] 55 154 49% 51%
SSA2 HSPA8* ATP binding protein 11 639 55% 66%
SSC1 HSPA9 Heat shock protein SSC1 13 654 85% 63%
STI1 STIP1 Heat shock protein STI1 25 589 8% 36%
TPI1 TPI1 Triose phosphate isomerase 67 248 55% 52%
TRX2 TXN Thioredoxin-2 21 104 19% 38%
TSA1 PRDX1 Peroxiredoxin TSA1 46 196 59% 59%
VMA10 ATP6V1G1* V-type proton ATPase subunit
G
22 114 64% 32%
Abbreviation: aa, amino acid.
*Additional orthologs are present in the human genome.
doi:10.1371/journal.pone.0163312.t003
Fig 11. Comparison of yeast, mouse, and human acyl-CoA-binding protein. Underlined regions denote peptides found in the
peptidome of yeast, mouse tissues and cell lines, and human cell lines. Double underline indicates multiple overlapping peptides found.
In mouse tissues, additional N-terminal peptides were found.
doi:10.1371/journal.pone.0163312.g011
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naturally occurringproducts of proteasome activity, and not artifactually-generatedpeptides
[19,21]. Finally, the finding that the yeast peptidome is remarkably similar to the peptidome of
human and mouse cells suggests that the generation and/or stability of the intracellular pep-
tides is conserved.Approximately one third of the yeast proteins that give rise to peptides
detected in the present study have human/mouse orthologs that give rise to peptides found in
previous studies on human and mouse cell lines and mouse tissues. In some cases, the yeast
and mammalian peptides arise from the same general region of the proteins, but these regions
do not appear to be more highly conserved than the parts of the protein that were not found in
the peptidome. This contrasts with proteins encoding neuropeptide precursors, in which the
regions corresponding to the bioactive peptides are more highly conserved than the other
regions of the proteins [56]. The proteasome is known to cleave proteins into peptides,
although the dogma in the field is that these peptides are rapidly degraded by intracellular ami-
nopeptidases [57]. However, there is no direct evidence to support this dogma, and studies on
the stability of peptides within cells have found that a subset appear to be more stable than oth-
ers [9,10]. Because proteasome inhibitors such as epoxomicin alter the levels of nearly all of the
peptides identified in human cells, it is likely that these peptides are proteasome products. The
small number of yeast peptides that were significantly affected by treatment with proteasome
inhibitors is consistent with the modest proteasome inhibition (30–40%) achieved in the pres-
ent study. Studies of HEK293T cells with 50 nM bortezomib for 1 hour caused a ~70% inhibi-
tion of proteasome activity and altered the level of most peptides, whereas a ten-fold lower
dose of bortezomib resulted in 15% inhibition and produced few changes in peptide levels
[20,21]. Despite using μM concentrations of inhibitors and yeast strains that lack several of the
major drug efflux pumps, only modest inhibition of proteasome activity was achieved, likely
due to the efficiencyof the remaining drug efflux pumps in the organism. Interestingly, the
paradoxical increase in levels of some peptides upon treatment of human cells with bortezomib
[20] was also observed in yeast (Fig 3, Table 2). Severalmechanisms have been proposed for
this effect, including bortezomib-mediated inhibition of downstream peptidases or changes in
the proteasome structure [20,22]. The finding that yeast peptides are also elevated by treatment
with bortezomib suggests that the mechanism for this paradoxical effect is common to yeast
and human cells.
The vast majority of yeast peptides arise from proteins that are among the top 20th percen-
tile in terms of abundance (Fig 7), based on a variety of large-scale approaches to measure lev-
els of protein, RNA, transcription, or translation [27,28,30–32,51]. A similar comparison of the
human cell line peptidome with RNA-seq data for those cell lines [33] also shows a strong cor-
relation of peptides with mRNA abundance (Fig 7). Although peptides in both yeast and
human cells are largely derived from abundant proteins and/or mRNAs, abundance alone is
not sufficient to predict whether peptides will be detected; only a small subset of the most
abundant proteins were detected in the peptidome. Furthermore, most proteins were repre-
sented by only one or two peptides, with N- and C-terminal fragments highly represented in
both the yeast and human cell line peptidomes. In theory, <1% of peptides should be derived
from the N- or C-termini of a protein, based on an average protein length of 300–400 amino
acids and average peptide length of 15 amino acids. Proteomic studies that digest proteins with
trypsin typically detect mostly internal peptides and only a small fraction of N- or C-terminal
peptides, which indicates that mass spectrometrydoes not favor N- or C-terminal fragments
[43]. One possibility to account for the high fraction of N- and C-terminal peptides is that they
are selectively produced within the cell. Another possibility is that N- and C-terminal peptides
may be more stable than other fragments. However, the amino acid composition of the pep-
tides detected in our analysis is comparable to the amino acid composition of intracellular and
nuclear yeast proteins, and is not enriched for amino acids that are resistant to proteases.
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Alternatively, the peptides could be protected from proteases by binding to intracellular pro-
teins. This latter idea is consistent with the proposal that intracellular peptides may have spe-
cific functions within cells that involve binding to other proteins [15,16].
In higher eukaryotes, endogenous intracellular peptides have been shown to regulate signal
transduction [58,59], intracellular calcium levels [59], and glucose uptake [60]. These studies
treated cells with synthetic peptides which corresponded to peptides identified in peptidomics
analyses of cells or tissues. A study in C. elegans found evidence that peptides produced by pro-
teolysis of mitochondrial proteins were released into the cytosol where they interacted with
transcription factors to regulate the mitochondrial unfolded protein response [61]. Endoge-
nous peptides encoded by mRNAs with short open reading frames were shown to affect tran-
scription inDrosophila [62]. These peptides induce proteasome-mediated processing of a
transcription repressor into a shorter activator [63]. Many additional studies have used syn-
thetic peptides to perturb protein folding or protein-protein interactions; for review see
[11,12,64–66]. Thus, peptides can clearly have a number of activities within cells.
The proteasome is commonly known to function in the degradation of unneeded or dam-
aged proteins. However, it is equally valid to consider the eukaryotic proteasome as a producer
of intracellular peptides. The catalytic core of the eukaryotic proteasome is structurally related
to the archaebacterial proteasome, which contains seven identical catalytically active subunits
[25]. Evolution added complexity to the comparatively simple prokaryotic proteasome—in
eukaryotes there are seven distinct beta subunits, only three of which are catalytically active.
This feature is conserved from yeast to humans, suggesting that the proteasome may have
evolved from a purely degradative function in prokaryotes to a peptide-generating function in
eukaryotes. In mammals, a small fraction of the peptides produced by the proteasome are dis-
played on cells in complex with MHC proteins and play a central role in the recognition of for-
eignmolecules.However, this function is only needed in higher eukaryotes with a functional
immune system (i.e. jawed vertebrates) [6]. The finding of the present study that peptides are
present in yeast, and that some of the peptides arise from orthologs of proteins found to pro-
duce intracellular peptides in human cells, supports the idea that the production of intracellular
peptides is an important biological process.
Supporting Information
S1 Appendix. Manual interpretation of Mascot results: Example of a peptide that matches
all of the criteria. Every peptide tentatively identified by Mascot is manually reviewed and
must match a number of criteria. These criteria are described this Appendix along with an
example of a peptide that is representative of a “weak” Mascot score, with discussion of the
decision process involved in accepting the identification.
(PDF)
S2 Appendix. Manual interpretation of Mascot results: Example of a peptide that does not
match the criteria. This Appendix shows an example of a peptide that has a “weak” Mascot
score and which was rejected because it failed to meet the criteria.
(PDF)
S1 Fig. Schematic diagramof TMAB labeling strategy for each LC/MS run on yeast pep-
tides. Four of the experiments started with two independent cultures each of wild-type (WT)
or pdr5Δ or snq2Δmutant yeast strains (top four panels). After growth to early log phase, each
culture was split into two equal volumes; one of which was treated for one hour with the indi-
cated proteasome inhibitor (bortezomib or epoxomicin, dissolved in DMSO), the other treated
with a comparable amount of DMSO (maximum 0.1%). Thus, each experiment included two
The Yeast Peptidome
PLOS ONE | DOI:10.1371/journal.pone.0163312 September 29, 2016 21 / 26
independent biological replicates for each control and treated strain. These four cultures were
then processed for peptidomics as described in Materials and Methods. The labeling strategy
for comparison of WT and blm10Δ strain yeast strains is shown in the lower panel. In all exper-
iments, peptides were labeled with TMAB-NHS isotopic labels as indicated.
(PDF)
S2 Fig. Alignments of proteins that are conservedbetween human and yeast.The regions of
the proteins that correspond to peptides found in the peptidome are indicated by underline. In
some cases, multiple peptides were found and are indicated by a double underline. If more
than 2 peptides found for a particular region of the protein, the additional peptides are not
indicated.
(PDF)
S1 Table. Yeast peptides (one row per peptide). Information includes peptide sequence,
mass, flanking residues, and name of gene and protein.
(XLSX)
S2 Table. Yeast proteins that give rise to the peptides reported in S1 Table (one row per
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